George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
It's all well and good getting the vaccines approved relative to varients, but the logistics of then getting them into arms and time scales involved will be considerable, suspect uptake will continue to decrease also.
Tomorrow brings us to the month which should be the biggest in Synairgens history and within 2 weeks of receiving P3 data internally. Who knows if read out will be late December or early January, it matters not. However the fact it could be within the calendar month from tomorrow just reaffirms how close we now are.
Thanks for the reply Dudio, I do appreciate all that. For what it's worth I think it's inevitable that the price will increase above £2 pending results, subject to no unforseen circumstances, the sp relative to risk/reward will the drive the price up.
Just thinking out loud really but in the build up to p3 results if the anticipated sp of say £4,£5,£6 (insert number) on opening is expected with favourable results, then is it not likely we could see a steady increase in price upto around £2.50 - £3 before the readout, or do people think it will hover much as it is now with a massive rocket when we get the results. Appreciate this is crystal ball territory and ultimately irrelevant for long term holders but it's the kind of thing I like to contemplate.
https://clinicaltrials.stanford.edu/browse-all-trials.html?ctid=NCT04518410
Take a look at this, among other things.
- In Phase III, meeting the protocol definition of being at "higher" risk of progression
to hospitalization or death (SNG001, SAB-185, BMS 986414+BMS 986413)